Citations

Mayo Clinic

Showing 10 of 108572 citations.

Significance of a positive tau PET scan with a negative amyloid PET scan
Robinson, Carling G. , Lee, Jeyeon , Min, Hoon‐Ki , Przybelski, Scott A. , Josephs, Keith A. , Graff‐Radford, Jonathan , Jack, Clifford R. , Petersen, Ronald C. , Fields, Julie A. , Lowe, Val J. , Lowe, Val J , Min, Hoon-Ki Paul , Jack, Clifford R , Jones, David T. , Boeve, Bradley F. , Knopman, David S. , Machulda, Mary M.

Alzheimer's & Dementia | December 30, 2023 | Volume: 20 | Issue: 3 | Pages: 1923-1932

10.1002/alz.13608 | PMID 38159060 Get It

AbstractINTRODUCTIONThe implications of positive tau positron emission tomography (T) with negative beta amyloid positron emission tomography (A) are not well understood. We investigated cognitive performance in participants who were T+ but A‐.METHODSWe evaluated 98 participants from the Mayo Clinic who were T+ and A‐. Participants were matched 2:1 to A‐ and T‐ cognitively unimpaired (CU) controls. Cognitive test scores were compared between different groups.RESULTSThe A‐T+ group demonstrated lower performance than the A‐T‐ group on the Mini‐Mental Status Exam (MMSE) (p < 0.001), Wechsler Memory Scale‐Revised Logical Memory I (p < 0.001) and Logical Memory II (p < 0.001), Auditory Verbal Learning Test (AVLT) delayed recall (p = 0.004), category fluency (animals p = 0.005; vegetables p = 0.021), Trail Making Test A and B (p < 0.001), and others. There were no significant differences in demographic features or apolipoprotein E (APOE) e4 genotype between CU A‐T+ and CI A‐T+.DISCUSSIONA‐T+ participants show an association with lower cognitive performance.
Quality improvement initiative to improve communication domains of patient satisfaction in a regional community hospital with Six Sigma methodology
Carsten, Brittan F, Bhandari, Pawan , Fortney, Benjamin J, Wilmes, Danielle S, Nelson, Cassandra M, Brien, Amy L, Walth, Rachel M, Anil, Gokhan

BMJ Open Quality | December 30, 2023 | Volume: 12 | Issue: 4 | Pages: e002306

10.1136/bmjoq-2023-002306 | PMID 38160018 Get It

Background Communication gaps, whether incomplete or fragmented communication, have been the cause of many disasters in human civilisation. Coordination of healthcare is directly related to proper communication and handoffs among multidisciplinary teams throughout multiple shifts during a patient’s hospitalisation. Local problem Patient surveys and direct patient feedback at Mayo Clinic Health System in Mankato, Minnesota, indicated that patient communication with physicians and nurses had declined in 2017 and 2018. Viewing this as an opportunity for improvement, our leadership initiated several changes to increase physician and nurse communication with patients, which resulted in no notable improvements. Methods A systematic quality improvement approach was implemented by using Six Sigma methodology. Stakeholders from multidisciplinary teams were assembled as the project team. The five steps of Six Sigma methodology (Define, Measure, Analyse, Improve and Control) were followed to create a quality improvement intervention. Intervention We developed a standardised and easy-to-use bedside team rounding tool to improve patient communication with physicians and nurses. Results Postintervention patient satisfaction top-box scores exceeded target improvements for both physician (from 78.5% to 82.0%, p<0.01) and nurse (from 80.5% to 83.1%, p=0.04) communication domains. Physicians had a 33-point increase in percentile rank (from 41st to 74th percentile rank), and nurses had a 25-point increase in percentile rank (from 59th to 84th percentile rank). This increase in communication ranked our institution at the top of national benchmark organisations. Conclusions Overwhelmingly positive patient feedback was achieved, and postintervention employee satisfaction was primarily positive when compared with preintervention satisfaction.
Primary Arthrodesis of Non-thumb Metacarpophalangeal Joints of the Hand: Clinical and Patient-Reported Outcomes
Rode, Matthew M. , Strother, Courtney Carlson , Welling, Benjamin D., Rizzo, Marco , Rode, Matthew , Welling, Benjamin D

HAND | December 30, 2023 | Volume: 20 | Issue: 3 | Pages: 445-452

10.1177/15589447231218457 | PMID 38158814 Get It

Background: Metacarpophalangeal (MCP) joint arthritis is common secondary to a variety of inflammatory, degenerative, and traumatic causes. Although MCP arthroplasty is more common for the second to fifth digits, primary arthrodesis can be used for high-demand patients with arthritis or unsalvageable fractures of the MCP joint. There has been limited recent studies on the outcomes of these patients. Methods: A retrospective review of 38 fingers in 27 patients with primary arthrodesis from 1990 to 2020 was conducted. The major outcomes were complications, reoperations, radiographic union, and time to union. Patient-reported outcomes including the Michigan Hand Outcomes Questionnaire and a questionnaire specific to the operative MCP joint were collected. Results: Rate of radiographic union was 84% including revisions. The average time to union was 3.6 months. Rates of complications, reoperation, and amputation were 26%, 16%, and 7%, respectively. Arthrodesis as part of emergent trauma reconstruction was significantly more likely to result in reoperation (50% vs 7%) and complication (63% vs 17%) than chronic arthritis. Patient-reported outcomes were fair to good with improvement in pain (79%), function (66%), and appearance (40%). Sixty-six percent (66%) of patients were satisfied with their surgery, and 73% would repeat the surgery. Conclusion: Arthrodesis for unsalvageable MCP fractures was associated with higher rates of reoperation and complication than inflammatory or degenerative arthritis. Excluding emergent trauma, MCP fusion was reliable with a reoperation rate of 7% and a modest complication rate of 17%. Patients rated reasonable levels of satisfaction and willingness to repeat the procedure despite complications.
Fatty acid synthase ( FASN ) signalome: A molecular guide for precision oncology
Menéndez, Javier A. , Steen, Travis Vander, Llop‐Hernández, Àngela , López, Júlia , Serrano‐Hervás, Eila , Lupu, Ruth , Vander Steen, Travis, Menendez, Javier A , Cuyàs, Elisabet , Encinar, José Antonio , Verdura, Sara , Osuna, Sílvia , Martı́n-Castillo, Begoña

Molecular Oncology | December 30, 2023 | Volume: 18 | Issue: 3 | Pages: 479-516

10.1002/1878-0261.13582 | PMID 38158755 Get It

The initial excitement generated more than two decades ago by the discovery of drugs targeting fatty acid synthase (FASN)‐catalyzed de novo lipogenesis for cancer therapy was short‐lived. However, the advent of the first clinical‐grade FASN inhibitor (TVB‐2640; denifanstat), which is currently being studied in various phase II trials, and the exciting advances in understanding the FASN signalome are fueling a renewed interest in FASN‐targeted strategies for the treatment and prevention of cancer. Here, we provide a detailed overview of how FASN can drive phenotypic plasticity and cell fate decisions, mitochondrial regulation of cell death, immune escape and organ‐specific metastatic potential. We then present a variety of FASN‐targeted therapeutic approaches that address the major challenges facing FASN therapy. These include limitations of current FASN inhibitors and the lack of precision tools to maximize the therapeutic potential of FASN inhibitors in the clinic. Rethinking the role of FASN as a signal transducer in cancer pathogenesis may provide molecularly driven strategies to optimize FASN as a long‐awaited target for cancer therapeutics.
Current Trends and New Approaches in Participatory Health Informatics
Petersen, Carolyn , Petersen, Carolyn , Denecke, Kerstin , Gabarrón, Elia

Methods of Information in Medicine | December 30, 2023 | Volume: 62 | Issue: 05/06 | Pages: 151-153

10.1055/s-0043-1777732 | PMID 38158213 Get It

Recommendations for reproducibility of cerebrospinal fluid extracellular vesicle studies
Sandau, Ursula S. , Magaña, Setty M. , Costa, Júlia , Nolan, John P. , Ikezu, Tsuneya , Vella, Laura J. , Jackson, Hannah K. , Palacio, Paola Loreto , Hill, Andrew F. , Keuren‐Jensen, Kendall Van , McFarland, Trevor J. , Palade, Joanna , Sribnick, Eric A. , Su, Huaqi , Vekrellis, Kostas , Coyle, Beth , Saugstad, Julie A. , Force, International Society for Extracellular Vesicles Cerebrospinal Fluid Task, Moreira, Lissette Retana , Hill, Andrew F , Quinn, Joseph F , Van Keuren-Jensen, Kendall R , McFarland, Trevor J , Sribnick, Eric A , Su, Huaqi , Vekrellis, Kostas , Coyle, Beth , Yang, You , Falcón-Perez, Juan Manual , Nieuwland, Rienk , Saugstad, Julie A , Ikezu, Tsuneya , Quinn, Joseph F. , Palade, Joanna , You, Yang , Falcón‐Pérez, Juan Manuel , Nieuwland, Rienk , Force, International Society for Extracellular Vesicles Cerebrospinal Fluid Task

Journal of Extracellular Vesicles | December 29, 2023 | Volume: 13 | Issue: 1 | Pages: No page available

10.1002/jev2.12397 | PMID 38158550 Get It

Abstract Cerebrospinal fluid (CSF) is a clear, transparent fluid derived from blood plasma that protects the brain and spinal cord against mechanical shock, provides buoyancy, clears metabolic waste and transports extracellular components to remote sites in the brain. Given its contact with the brain and the spinal cord, CSF is the most informative biofluid for studies of the central nervous system (CNS). In addition to other components, CSF contains extracellular vesicles (EVs) that carry bioactive cargoes (e.g., lipids, nucleic acids, proteins), and that can have biological functions within and beyond the CNS. Thus, CSF EVs likely serve as both mediators of and contributors to communication in the CNS. Accordingly, their potential as biomarkers for CNS diseases has stimulated much excitement for and attention to CSF EV research. However, studies on CSF EVs present unique challenges relative to EV studies in other biofluids, including the invasive nature of CSF collection, limited CSF volumes and the low numbers of EVs in CSF as compared to plasma. Here, the objectives of the International Society for Extracellular Vesicles CSF Task Force are to promote the reproducibility of CSF EV studies by providing current reporting and best practices, and recommendations and reporting guidelines, for CSF EV studies. To accomplish this, we created and distributed a world‐wide survey to ISEV members to assess methods considered ‘best practices’ for CSF EVs, then performed a detailed literature review for CSF EV publications that was used to curate methods and resources. Based on responses to the survey and curated information from publications, the CSF Task Force herein provides recommendations and reporting guidelines to promote the reproducibility of CSF EV studies in seven domains: (i) CSF Collection, Processing, and Storage; (ii) CSF EV Separation/Concentration; (iii) CSF EV Size and Number Measurements; (iv) CSF EV Protein Studies; (v) CSF EV RNA Studies; (vi) CSF EV Omics Studies and (vii) CSF EV Functional Studies.
Kidney Function in Patients With Adrenal Adenomas: A Single-Center Retrospective Cohort Study
Rahimi, Leili , Kittithaworn, Annop , Garcia, Raul Gregg , Saini, Jasmine , Dogra, Prerna , Atkinson, Elizabeth J. , Achenbach, Sara J., Kattah, Andrea G. , Gregg Garcia, Raul, Kattah, Andrea, Bancos, Irina , Saini, Jasmine , Garcia, Raul G , Bancos, Irina

The Journal of Clinical Endocrinology & Metabolism | December 29, 2023 | Volume: 109 | Issue: 9 | Pages: e1750-e1758

10.1210/clinem/dgad765 | PMID 38157409 Get It

Abstract Context Patients with nonfunctioning adrenal adenomas (NFA) and mild autonomous cortisol secretion (MACS) demonstrate an increased risk of chronic kidney disease (CKD); however, factors associated with CKD are unknown. Objective We aimed to identify the factors associated with CKD and assess the effect of adrenalectomy on kidney function in patients with NFA or MACS. Methods A single-center cohort study of patients with NFA and MACS, 1999 to 2020, was conducted. MACS was diagnosed based on post dexamethasone suppression test (DST) cortisol greater than or equal to 1.8 mcg/dL. Age, sex, dysglycemia, hypertension, therapy with statin, angiotensin-converting enzyme inhibitor, or angiotensin II receptor blocker were included in the multivariable analysis. Outcomes included estimated glomerular filtration rate (eGFR) at the time of diagnosis with MACS or NFA and postadrenalectomy delta eGFR. Results Of 972 patients, 429 (44%) had MACS and 543 (56%) had NFA. At the time of diagnosis, patients with MACS had lower eGFR (median 79.6 vs 83.8 mL/min/1.73 m2; P &lt; .001) than patients with NFA. In a multivariable analysis, factors associated with lower eGFR were older age, hypertension, and higher DST. In 204 patients (MACS: 155, 76% and NFA: 49, 24%) treated with adrenalectomy, postadrenalectomy eGFR improved in both groups starting at 18 months up to 3.5 years of follow-up. Factors associated with increased eGFR were younger age, lower preadrenalectomy eGFR, and longer follow-up period. Conclusion DST cortisol is an independent risk factor for lower eGFR in patients with adrenal adenomas. Patients with both MACS and NFA demonstrate an increase in eGFR post adrenalectomy, especially younger patients with lower eGFR pre adrenalectomy.
Analgesia in Transcutaneous Laryngeal Botulinum Toxin Injections: A Randomized Crossover Trial
Heyes, Richard , Lott, David G. , Karle, William E. , Lott, David G , Karle, William E , Adler, Charles H. , Yee, Claire

The Laryngoscope | December 29, 2023 | Volume: 134 | Issue: 5 | Pages: 2277-2281

10.1002/lary.31208 | PMID 38157199 Get It

ObjectivesThere is an absence of data in the literature regarding methods to improve the patient experience during the performance of awake in‐office laryngeal injections. This study sought to evaluate whether the use of local anesthetic or a vibrating instrument decreased overall pain experienced by patients with laryngeal dystonia, frequently referred to as spasmodic dysphonia (SD), undergoing transcervical botulinum toxin injections.MethodsThis was an unblinded, prospective randomized control trial with a crossover design where each patient received transcutaneous transcricothyroid injection of botulinum toxin with alternating use of no anesthesia, local anesthesia (2% lidocaine in 1:100,000 epinephrine), and vibrating instrument in three consecutive laryngeal injections to treat adductor SD. Patients were randomized to the order they received these treatments. Patients measured pain on a 0–10 visual analogue scale (VAS) and selected their preferred technique after receiving all three analgesic modalities.ResultsThirty‐two patients completed the study. There was no statistically significant difference in pain between the three analgesic techniques (p = 0.38). The most preferred analgesic technique was the vibrating wand (44% (14/32)). Lidocaine was the second most preferred (37% (12/32)) and 19% (6/32) of patients preferred nothing. When combining the wand and nothing groups, 63% of patients preferred one of these two methods (95% exact CI: 44%–79%).ConclusionThere was no statistically significant difference in median pain experienced by patients during laryngeal botulinum toxin injection between these different analgesic modalities. More than half of the patients selected a preference for a technique that did not include lidocaine. This data supports individualization of analgesia during transcutaneous laryngeal injections.Level of Evidence2 Laryngoscope, 134:2277–2281, 2024
Improving our treatment of breast cancer during pregnancy
O’Sullivan, Ciara C. , Ruddy, Kathryn J.

JNCI: Journal of the National Cancer Institute | December 29, 2023 | Volume: 116 | Issue: 2 | Pages: 183-185

10.1093/jnci/djad259 | PMID 38156705 Get It

Emerging Antibody-Drug Conjugate Therapies and Targets for Metastatic Renal Cell Carcinoma
Gottlich, Harrison C., Pessoa, Rodrigo Rodrigues , Mahmoud, Ahmed , Garg, I. D. , Orme, Jacob J. , Costello, Brian A. , Cheville, John C. , Mahmoud, Ahmed M , Nabavizadeh, Reza , Dumbravă, Mihai , Garg, Ishita, Lucien, Fabrice

Kidney Cancer | December 29, 2023 | Volume: 7 | Issue: 1 | Pages: 161-172

10.3233/kca-230012 Get It

Background: Approximately 30% of renal cell carcinoma (RCC) cases present with de novo metastatic disease, while 20% to 30% of those with localized disease will develop metastases following surgical resection. Various drug classes have been investigated to treat RCC, including cytokine-based therapies, small molecule Vascular Endothelial Growth Factor (VEGF) tyrosine kinase inhibitors (TKIs) and antibody-based therapies. Up to 58% of patients fail to respond to primary immune checkpoint inhibitor (ICI) therapy, and nearly all initial responders experience disease progression due to the development of secondary resistance. Consequently, novel treatment options are being investigated. Objective: Review the rapidly evolving ADC therapeutic landscape in metastatic RCC including recent trials, emerging ADCs targets, and future directions for ADCs in the treatment of advanced RCC. Methods: Literature review using the MEDLINE database on important trials and presentations from the American Society of Clinical Oncology (ASCO), and the European Society for Medical Oncology (ESMO) conferences. Key words used included “renal cell carcinoma,” “RCC,” “metastatic RCC,” “advanced RCC,” “antibody-based therapies,” “immunotherapy,” “clinical trials,” and “emerging drugs.” Specifically for review of ADCs in RCC, the following search string was used with additional review of bibliographies from retrieved papers: “((antibody drug conjugate) OR (antibody-dependent cellular cytotoxicity) OR (chimeric antigen receptor)) AND ((kidney cancer) OR (renal cell carcinoma))”. Results: Several promising targets including MMP14, EGFR, MCT4, CA9, MET, CDH13, B7-H3, and PSMA were identified with relevant preclinical and clinical studies reviewed. Conclusions: While ADCs therapeutics have not shown benefit to date for renal cell carcinoma, there are ample promising candidates and targets for future research.